Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2013

View Archived Issues

Chugai Pharmaceutical updates progress of second quarter 2013

Daiichi Sankyo set to expand drug discovery program

KU Leuven and Fit Biotech to collaborate on novel immunotherapeutics

Inhibition of FXII activation shows potential for thromboprophylaxis

Novel mutation in the CACNA1H gene identified in classic idiopathic generalized epilepsies

Novel tool to analyze drug and target binding optimization in cells and tissues

Antitope and ChemomAb to generate human antibodies against inflammatory diseases

Researchers identify CGRP receptor gene SNPs associated with migraine

Chelsea Therapeutics provides update on Northera NDA

MDxHealth and Bostwick enter marketing agreement for prostate cancer diagnostic

Pfizer reports pipeline developments of second quarter 2013

Norgine discontinues development of NRL-972

Teva reports formation of global Huntington's disease research collaboration

MC-710 shows safety and efficacy in phase II trials in patients with hemophilia

Researchers at Bayer design new sGC and PDE5 inhibitors

Novel PBK/Akt inhibitors for cancer presented by Bayer

Ajinomoto Pharmaceuticals discontinues development of AJG-501

Isis earns milestone from GSK for advancement of ISIS-TTR Rx program

Catabasis reports encouraging results from phase I trial of CAT-2003

ImmunoCellular Therapeutics' anticancer vaccine enters phase I trial in recurrent GBM

AstraZeneca and FibroGen enter collaboration for FG-4592

Flutiform recommended for approval in Japan

Adasuve launched in Europe for agitation in patients with schizophrenia or bipolar disorder

AEterna Zentaris initiates phase III trial of zoptarelin doxorubicin for endometrial cancer

Elusys reports data on Anthim given via intramuscular administration to anthrax-exposed animals

Phase IIa rheumatoid arthritis study planned for RHB-104

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...